Supply Chain

U.S Reps. Jason Chaffetz (R-Utah) and Elijah Cummings (D-Md.) of the House Committee on Oversight and Government Reform on Monday sent a letter to Mylan CEO Heather Bresch requesting documents and communications regarding the EpiPen price hike, according to Reuters.

The Food and Drug Administration recently approved a new flu immunization developed by Cambridge, Mass.-based Seqirus.

Drugmakers are pouring money into an increasingly popular marketing tactic — the unbranded ad. In a less regulated attempt to reach consumers, drug companies create ads that seek to educate the public on a specific health condition, one the company…

The Food and Drug Administration granted Fast Track designation for APL-130277, an experimental treatment for Parkinson's disease created by Toronto-based Cynapsus Therapeutics.

The Food and Drug Administration granted emergency use authorization for a new Zika diagnostic test developed by Switzerland-based Roche.

In response to public outrage over the EpiPen price hike, pharmaceutical company Mylan said it will introduce an identical generic version with a wholesale list price of $300 for a pack of two, instead of more than $600 for the…

Former Turing Pharmaceutical CEO Martin Shkreli said via Twitter that insurers should cover some of the cost to make the drug more affordable, according to USA Today.

A bipartisan group of senators on Wednesday sent a letter to Food and Drug Administration Commissioner Robert Califf, MD, urging the agency to help bring more EpiPen competitors to the market.

After Mylan CEO Heather Bresch blamed the pharmaceutical "middlemen" for causing the high price of EpiPens in an interview Thursday, Steve Miller, MD, CMO of Express Scripts, countered that her statement couldn't be "farther from the truth," reported CNBC.

Heather Bresch, the Mylan CEO at the center of the EpiPen pricing controversy, addressed scrutiny over the Canonsburg, Pa.-based company's pricing practices in a televised interview Thursday on CNBC.